Adherence, insight and disability in paranoid schizophrenia.

Related Articles

Adherence, insight and disability in paranoid schizophrenia.

Psychiatry Res. 2018 Sep 23;270:274-280

Authors: García-Cabeza I, Díaz-Caneja CM, Ovejero M, de Portugal E

Abstract
Insight has long been linked to both prognosis and functioning in patients with schizophrenia; likewise, it is key to treatment adherence. This study seeks to assess the association between insight, adherence to pharmacological treatment, and disability in schizophrenia, and to study the potential mediating role of adherence between insight and disability. Insight (SUMD), adherence (CRS), and disability (WHO-DAS) were measured in 80 clinically stable patients with DSM-IV TR paranoid schizophrenia. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). In a first step, predictors of disability were identified using linear regression to identify variables related to disability and further a mediation analysis was carried out. Negative symptoms, insight, and adherence account for 54.2% of the variance in disability. Negative symptoms act directly on disability, while the effect of insight on disability is partially mediated by adherence. Insight is key in disability in schizophrenia and should be leveraged in treatment programs.

PMID: 30278408 [PubMed - as supplied by publisher]